Literature DB >> 2213165

Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas.

E F Adams1, U M Schrell, R Fahlbusch, P Thierauf.   

Abstract

Cell culture and biochemical techniques have been employed to examine the effects of steroids, bromocriptine, and epidermal growth factor (EGF) on the growth and proliferative potential of meningiomas. In cell culture, the growth of meningiomas was not altered by progestogens, antiprogestogens, or 17beta-estradiol. The progestogen, norethisterone, had no effect on the uptake by meningiomas cell cultures of 3H-thymidine. Furthermore, cytosolic deoxyribonucleic acid (DNA) polymerase activity of meningiomas did not correlate with the progesterone receptor status of the same tumors. In contrast, the androgen antagonists, cyproterone acetate and 11-alpha-hydroxyprogesterone, and the dopamine agonist, bromocriptine, all inhibited the in vitro growth of meningioma cells. The growth of meningioma cell cultures was stimulated by EGF, and there was a positive correlation between the EGF content and DNA polymerase activity in meningioma cytosols. These results demonstrate that female sex steroids do not influence growth of meningiomas in vitro, whereas antiandrogens and bromocriptine have an antiproliferative effect. Consequently, bromocriptine and antiandrogens may have a role in the medical treatment of meningiomas. In addition, these results suggest that EGF may be involved in the genesis and/or progression of meningiomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213165     DOI: 10.3171/jns.1990.73.5.0750

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.

Authors:  Francesco Maiuri; Marialaura Del Basso De Caro; Felice Esposito; Paolo Cappabianca; Viviana Strazzullo; Guido Pettinato; Enrico de Divitiis
Journal:  J Neurooncol       Date:  2007-01-17       Impact factor: 4.130

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

3.  Human meningiomas possess muscarinic acetylcholine receptors: stimulation of phosphatidylinositol turnover by carbachol.

Authors:  E F Adams; A Hüttner; T Lei; B Rafferty; U Schrell; R Fahlbusch
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

Review 4.  Orbital meningiomas: surgery, radiotherapy, or hormones?

Authors:  G E Rose
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

5.  Small heat-shock protein is expressed in meningiomas and in granulofilamentous inclusion bodies.

Authors:  N Yokoyama; T Iwaki; J E Goldman; J Tateishi; M Fukui
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

Authors:  R Maggio; M Armogida; M Scarselli; F Salvadori; B Longoni; C Pardini; A Chiarenza; S Chiacchio; F Vaglini; R Bernardini; A Colzi; G U Corsini
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

7.  Involvement of protein kinase C in growth regulation of human meningioma cells.

Authors:  T Todo; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 8.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

Review 9.  Chemotherapy for meningiomas.

Authors:  A P Kyritsis
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

10.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

Authors:  J W Goodwin; J Crowley; H J Eyre; B Stafford; K A Jaeckle; J J Townsend
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.